Abstract
Objective:
To assess patient acceptability of a novel dry powder inhaler (DPI), Clickhaler® (Innovata Biomed Ltd., the Respiratory Division of ML Laboratories PLC) in routine clinical use as a first-line bronchodilator treatment.
Design:
In a multicentre open label study, asthma patients taking bronchodilators via a metered dose inhaler (MDI) or DPI (Turbohaler®) were given salbutamol via the Clickhaler®. Questionnaires before and after four weeks of treatment were used to assess the clinicians' and patients' opinions of the device.
Subjects:
184 asthma patients aged ≥18 years, showing a good DPI technique.
Results:
Of the 175 patients completing the study, 121 found the Clickhaler® as easy (30%) or easier (39%) to use than their pre-study inhaler and 87 patients (50%) liked the Clickhaler® as much as (15%) or more than (35%) their pre-study inhaler. Investigators considered it more suitable (26%) /as suitable (39%) as the pre-study device for 65% of patients. Correct technique was easy to teach and was maintained by 98% of the patients after four weeks.
Conclusion:
The Clickhaler® is easy to operate and well accepted by adult asthma patients.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allen, M., Anderson, P., Barnes, N. et al. Assessing the acceptability of a novel dry powder inhaler A multicentre study in adult asthmatic patients using routine bronchodilator therapy. Prim Care Respir J 10, 8–11 (2001). https://doi.org/10.1038/pcrj.2001.4
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/pcrj.2001.4